Skip to main content
SpringerLink
Log in

Angiogenese in Reproduktionsmedizin und gynäkologischer Onkologie

Angiogenesis in reproduction medicine and gynecological oncolology

  • Leitthema
  • Published:
Der Gynäkologe Aims and scope

Zusammenfassung

Angiogenese bezeichnet das Wachstum von Blutgefäßen aus einem vorgebildeten Kapillarsystem. Angiogenese ist ein physiologischer Prozess bei Entwicklung und Wachstum von Geweben und Organen. Die Blutgefäßentwicklung wird durch eine Veränderung des Gleichgewichts zwischen pro- und antiangiogenen Faktoren induziert. Angiogenese spielt in der Kontrolle des Menstruationszyklus sowie bei Implantation und Wachstum der Plazenta eine wichtige Rolle. Bei vielen Erkrankungen in der Gynäkologie und Geburtshilfe (z. B. ovarielles Hyperstimulationssyndrom, Endometriose, Präeklampsie) ist die Regulation angiogener Prozesse gestört. Angiogenese ist auch beim Wachstum und der Metastasierung maligner Tumoren von essentieller Bedeutung. Inhibitoren der Tumorangiogenese sind in den Blickpunkt neuer Therapiestrategien gekommen. Die Wirksamkeit des antiangiogenen Antikörpers Bevacizumab in der Behandlung von metastasierendem Brustkrebs wurde nachgewiesen. Der Beitrag gibt eine Übersicht über die Rolle der Angiogenese in der Reproduktionsmedizin und der gynäkologischen Onkologie mit Akzentuierung der klinischen Relevanz.

Abstract

Angiogenesis is a physiological process involving the growth of new blood vessels from pre-existing vessels. The formation of new blood vessels is a normal and vital process in growth and development. The switch to the angiogenic phenotype is induced by a change in the balance of positive and negative regulators of angiogenesis. Angiogenesis plays an important role in the regulation of the female menstrual cycle. In prenatal medicine the formation of blood vessels is also significant for implantation and for the development of the placenta. The regulation of angiogenetic processes is defective in many gynecological and obstetric diseases (e.g. ovarian hyperstimulation syndrome, endometriosis and preeclampsia). Angiogenesis also plays an important role in the growth and metastasization of malignant tumors. Inhibition of tumor angiogenesis has become the focus of new treatment strategies. The efficacy of the anti-angiogenic antibody bevacizumab in the treatment of metastatic breast cancer has been demonstrated. This article gives an overview of the role of angiogenesis in the female reproductive system and in gynecological oncology with the main focus on the clinical significance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Auguste P, Javerzat S, Bikfalvi A (2003) Regulation of vascular development by fibroblast growth factors. Cell Tissue Res 314:157–166

    Article  CAS  PubMed  Google Scholar 

  2. Augustin HG, Braun K, Telemenakis I et al (1995) Ovarian angiogenesis. Phenotypic characterization of endothelial cells in a physiological model of blood vessel growth and regression. Am J Pathol 147:339–351

    CAS  PubMed  Google Scholar 

  3. Becker CM, D’Amato RJ (2007) Angiogenesis and antiangiogenic therapy in endometriosis. Microvasc Res 74:121–130

    Article  CAS  PubMed  Google Scholar 

  4. Burger RA (2007) Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol 25:2902–2908

    Article  CAS  PubMed  Google Scholar 

  5. Cannistra SA, Matulonis UA, Penson RT et al (2007) Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25:5180–5186

    Article  CAS  PubMed  Google Scholar 

  6. Cao Y (2001) Endogenous angiogenesis inhibitors and their therapeutic implications. Int J Biochem Cell Biol 33:357–369

    Article  CAS  PubMed  Google Scholar 

  7. Carmeliet P (2005) Angiogenesis in life, disease and medicine. Nature 438:932–936

    Article  CAS  PubMed  Google Scholar 

  8. Davis S, Yancopoulos GD (1999) The angiopoietins: Yin and Yang in angiogenesis. Curr Top Microbiol Immunol 237:173–185

    CAS  PubMed  Google Scholar 

  9. Eberhard A, Kahlert S, Goede V et al (2000) Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 60:1388–1393

    CAS  PubMed  Google Scholar 

  10. Ferrara N, Chen H, Davis-Smyth T et al (1998) Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med 4:336–340

    Article  CAS  PubMed  Google Scholar 

  11. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186

    CAS  PubMed  Google Scholar 

  12. Fraser HM, Wulff C (2003) Angiogenesis in the corpus luteum. Reprod Biol Endocrinol 1:88

    Article  PubMed  Google Scholar 

  13. Geva E, Jaffe RB (2000) Role of vascular endothelial growth factor in ovarian physiology and pathology. Fertil Steril 74:429–438

    Article  CAS  PubMed  Google Scholar 

  14. Gomez-Raposo C, Mendiola M, Barriuso J et al (2009) Angiogenesis and ovarian cancer. Clin Transl Oncol 11:564–571

    Article  PubMed  Google Scholar 

  15. Gordon JD, Shifren JL, Foulk RA et al (1995) Angiogenesis in the human female reproductive tract. Obstet Gynecol Surv 50:688–697

    Article  CAS  PubMed  Google Scholar 

  16. Hamilton CA, Maxwell GL, Chernofsky MR et al (2008) Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. Gynecol Oncol 111:530–532

    Article  CAS  PubMed  Google Scholar 

  17. Hawighorst T, Hussein F, Stein W et al (2008) Anti-angiogenesis: Moving from preclinical research to clinical application. Geburtshilfe Frauenheilkd 68:397–403

    Article  CAS  Google Scholar 

  18. Hawighorst T, Oura H, Streit M et al (2002) Thrombospondin-1 selectively inhibits early-stage carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic mice. Oncogene 21:7945–7956

    Article  CAS  PubMed  Google Scholar 

  19. Hawighorst T, Velasco P, Streit M et al (2001) Thrombospondin-2 plays a protective role in multistep carcinogenesis: a novel host anti-tumor defense mechanism. EMBO J 20:2631–2640

    Article  CAS  PubMed  Google Scholar 

  20. Holmgren L, O’Reilly MS, Folkman J (1995) Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1:149–153

    Article  CAS  PubMed  Google Scholar 

  21. Jaffe RB (2000) Importance of angiogenesis in reproductive physiology. Semin Perinatol 24:79–81

    Article  CAS  PubMed  Google Scholar 

  22. Kamat AA, Merritt WM, Coffey D et al (2007) Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res 13:7487–7495

    Article  CAS  PubMed  Google Scholar 

  23. Khosravi Shahi P, Soria Lovelle A, Perez Manga G (2009) Tumoral angiogenesis and breast cancer. Clin Transl Oncol 11:138–142

    Article  Google Scholar 

  24. Lawler J, Detmar M (2004) Tumor progression: the effects of thrombospondin-1 and -2. Int J Biochem Cell Biol 36:1038–1045

    Article  CAS  PubMed  Google Scholar 

  25. Levine RJ, Maynard SE, Qian C et al (2004) Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350:672–683

    Article  CAS  PubMed  Google Scholar 

  26. Loges S, Mazzone M, Hohensinner P, Carmeliet P (2009) Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 15:167–170

    Article  CAS  PubMed  Google Scholar 

  27. Maynard SE, Min JY, Merchan J et al (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension and proteinuria in preeclampsia. J Clin Invest 111:649–658

    CAS  PubMed  Google Scholar 

  28. Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666–2676

    Article  CAS  PubMed  Google Scholar 

  29. Pasquale EB (2010) Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 10:165–180

    Article  CAS  PubMed  Google Scholar 

  30. Reynolds LP, Borowicz PP, Caton JS et al (n d) Uteroplacental vascular development and placental function: an update. Int J Dev Biol 54:355–366

  31. Roberts JM, Taylor RN, Musci TJ et al (1989) Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 161:1200–1204

    CAS  PubMed  Google Scholar 

  32. Selvaggi L, Ribatti D, Loverro G et al (1995) Angiogenesis in pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 59:83–89

    Article  CAS  PubMed  Google Scholar 

  33. Senger DR, Connolly DT, Van de Water L et al (1990) Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res 50:1774–1778

    CAS  PubMed  Google Scholar 

  34. Shokry M, Bedaiwy MA, Fathalla MM et al (2010) Maternal serum placental growth factor and soluble fms-like tyrosine kinase 1 as early predictors of preeclampsia. Acta Obstet Gynecol Scand 89:143–146

    Article  CAS  PubMed  Google Scholar 

  35. Torry DS, Holt VJ, Keenan JA et al (1996) Vascular endothelial growth factor expression in cycling human endometrium. Fertil Steril 66:72–80

    CAS  PubMed  Google Scholar 

  36. Tsampalas M, Gridelet V, Berndt S et al (2010) Human chorionic gonadotropin: A hormone with immunological and angiogenic properties. J Reprod Immunol

  37. Verlohren S, Galindo A, Schlembach D et al (2010) An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 202:161 e161–161 e111

    Article  PubMed  Google Scholar 

  38. Wang A, Rana S, Karumanchi SA (2009) Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology (Bethesda) 24:147–158

    Google Scholar 

  39. Yancopoulos GD, Davis S, Gale NW et al (2000) Vascular-specific growth factors and blood vessel formation. Nature 407:242–248

    Article  CAS  PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Klinik für Gynäkologie und Geburtshilfe, Universitätsmedizin, Georg-August-Universität Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Deutschland

    T. Hawighorst, W. Stein, C. Gründker & G. Emons

Authors
  1. T. Hawighorst
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. Stein
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Gründker
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Emons
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Hawighorst.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hawighorst, T., Stein, W., Gründker, C. et al. Angiogenese in Reproduktionsmedizin und gynäkologischer Onkologie. Gynäkologe 43, 595–600 (2010). https://doi.org/10.1007/s00129-010-2532-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00129-010-2532-6

Schlüsselwörter

Keywords

Search

Navigation